Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
종목 코드 PCRX
회사 이름Pacira Biosciences Inc
상장일Feb 03, 2011
CEOMr. Frank D. Lee
직원 수790
유형Ordinary Share
회계 연도 종료Feb 03
주소2000 Sierra Point Parkway
도시BRISBANE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호94005
전화16502428052
웹사이트https://www.pacira.com/
종목 코드 PCRX
상장일Feb 03, 2011
CEOMr. Frank D. Lee
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음